경구 고형 제제 CDMO 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 메커니즘별, 약효별, 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Oral Solid Dosage CDMO Market Summary

The global oral solid dosage CDMO market size was estimated at USD 43.65 billion in 2024 and is projected to reach USD 77.06 billion by 2033, growing at a CAGR of 6.56% from 2025 to 2033. The market growth is driven by a rising demand for cost-efficient drug development, increasing outsourcing by pharmaceutical and biotech companies, and growing consumption of tablets and capsules for chronic and lifestyle diseases, owing to ease of administration and precise dosage, which enhances the requirement for oral solid dosage CDMO services.

Other factors contributing to market growth include the expansion of generic drugs, patent expiries, and the need for flexible manufacturing capacity. Most companies rely on CDMOs to access advanced formulation capabilities, scale up production efficiently, and meet stringent regulatory and quality requirements. In addition, technological advancement and increased reliance on CDMOs for end-to-end OSD development and manufacturing services are expected to drive the market.

The growing prevalence of chronic and infectious diseases is a significant factor driving the demand for novel therapies. In addition, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel therapies. Another factor contributing to market growth is adverse drug reactions to existing drugs, which have increased the demand for novel treatment options.

Moreover, several solid dosage forms are currently available on the market due to ongoing advancements in drug delivery technology, rising investments by contract development and manufacturing organizations (CDMOs) to expand OSD development, and increasing demand for novel therapies, all of which further contribute to market growth.

Global Oral Solid Dosage Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral solid dosage CDMO market report based on product, mechanism, drug potency, service, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Tablets
  • Compressed Tablets
  • Orally Disintegrating Tablets (ODT)
  • Chewable Tablets
  • Bi-layer or Tri-layer Tablets
  • Sublingual or Buccal Tablets
  • Others
• Capsules
  • Hard Gelatin Capsules
  • Soft Gelatin Capsules
• Powders
• Granules
• Others
• Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
• Immediate Release
• Delayed Release
• Controlled Release
• Drug Potency Outlook (Revenue, USD Million, 2021 - 2033)
• High Potent Drugs
• Moderate Potent Drugs
• Low Potent Drugs
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
• Contract Manufacturing
• Packaging and Labelling
• Regulatory Affairs
• Logistics & Storage
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Large Size Companies
• Medium & Small Size Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Mechanism
  • 1.2.3. Drug Potency
  • 1.2.4. Service
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Oral Solid Dosage CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Oral Solid Dosage CDMO Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Oral Solid Dosage CDMO Market: Product Movement Analysis
• 4.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.5. Tablets
  • 4.5.1. Tablets Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.5.2. Compressed Tablets
    • 4.5.2.1. Compressed Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Orally Disintegrating Tablets (ODT)
    • 4.5.3.1. Orally Disintegrating Tablets (ODT) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Chewable Tablets
    • 4.5.4.1. Chewable Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Bi-layer or Tri-layer Tablets
    • 4.5.5.1. Bi-layer or Tri-layer Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5.6. Sublingual or Buccal Tablets
    • 4.5.6.1. Sublingual or Buccal Tablets Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5.7. Others
    • 4.5.7.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.6. Capsules
  • 4.6.1. Capsules Market Estimates & Forecasts, 2021 to 2033 (USD Million)
  • 4.6.2. Hard Gelatin Capsules
    • 4.6.2.1. Hard Gelatin Capsules Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Soft Gelatin Capsules
    • 4.6.3.1. Soft Gelatin Capsules Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.7. Powder
  • 4.7.1. Powder Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.8. Granules
  • 4.8.1. Granules Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oral Solid Dosage CDMO Market: Mechanism Estimates & Trend Analysis

• 5.1. Mechanism Market Share, 2024 & 2033
• 5.2. Mechanism Segment Dashboard
• 5.3. Global Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
• 5.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Mechanism, 2021 to 2033 (USD Million)
• 5.5. Immediate Release
  • 5.5.1. Immediate Release Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.6. Delayed Release
  • 5.6.1. Delayed Release Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 5.7. Controlled Release
  • 5.7.1. Controlled Release Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oral Solid Dosage CDMO Market: Drug Potency Estimates & Trend Analysis

• 6.1. Drug Potency Market Share, 2024 & 2033
• 6.2. Drug Potency Segment Dashboard
• 6.3. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
• 6.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Drug Potency, 2021 to 2033 (USD Million)
• 6.5. High Potent Drugs
  • 6.5.1. High Potent Drugs Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 6.6. Moderate Potent Drugs
  • 6.6.1. Moderate Potent Drugs Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 6.7. Low Potent Drugs
  • 6.7.1. Low Potent Drugs Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oral Solid Dosage CDMO Market: Service Estimates & Trend Analysis

• 7.1. Service Market Share, 2024 & 2033
• 7.2. Service Segment Dashboard
• 7.3. Oral Solid Dosage CDMO Market: Service Movement Analysis
• 7.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 7.5. Contract Development
  • 7.5.1. Contract Development Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.6. Contract Manufacturing
  • 7.6.1. Contract Manufacturing Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.7. Packaging and Labelling
  • 7.7.1. Packaging and Labelling Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.8. Regulatory Affairs
  • 7.8.1. Regulatory Affairs Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.9. Logistics & Storage
  • 7.9.1. Logistics & Storage Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Oral Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2024 & 2033
• 8.2. End Use Segment Dashboard
• 8.3. Oral Solid Dosage CDMO Market: End Use Movement Analysis
• 8.4. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.5. Large Size Companies
  • 8.5.1. Large Size Companies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.6. Medium & Small Size Companies
  • 8.6.1. Medium & Small Size Companies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 8.7. Others
  • 8.7.1. Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Oral Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Oral Solid Dosage CDMO Market: Regional Movement Analysis
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 9.4. North America
  • 9.4.1. North America Oral Solid Dosage CDMO Market Estimates & Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework
    • 9.4.2.3. U.S. Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework
    • 9.4.3.3. U.S. Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework
    • 9.4.4.3. Mexico Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework
    • 9.5.2.3. UK Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework
    • 9.5.3.3. Germany Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework
    • 9.5.4.3. France Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework
    • 9.5.5.3. Italy Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework
    • 9.5.6.3. Spain Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Regulatory Framework
    • 9.5.7.3. Denmark Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Regulatory Framework
    • 9.5.8.3. Sweden Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Regulatory Framework
    • 9.5.9.3. Norway Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework
    • 9.6.2.3. Japan Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Regulatory Framework
    • 9.6.3.3. China Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Regulatory Framework
    • 9.6.4.3. India Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Regulatory Framework
    • 9.6.5.3. Australia Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Regulatory Framework
    • 9.6.6.3. South Korea Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Regulatory Framework
    • 9.6.7.3. Thailand Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework
    • 9.7.2.3. Japan Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework
    • 9.7.3.3. China Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Regulatory Framework
    • 9.8.2.3. South Africa Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Regulatory Framework
    • 9.8.3.3. Saudi Arabia Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Regulatory Framework
    • 9.8.4.3. UAE Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Regulatory Framework
    • 9.8.5.3. Kuwait Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.6. Qatar
    • 9.8.6.1. Key Country Dynamics
    • 9.8.6.2. Regulatory Framework
    • 9.8.6.3. Qatar Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 9.8.7. Oman
    • 9.8.7.1. Key Country Dynamics
    • 9.8.7.2. Regulatory Framework
    • 9.8.7.3. Oman Oral Solid Dosage CDMO Market Estimates & Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Lonza
    • 10.5.1.1. Company Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Thermo Fisher Scientific Inc.
    • 10.5.2.1. Company Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Cambrex Corporation
    • 10.5.3.1. Company Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Catalent, Inc.
    • 10.5.4.1. Company Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Siegrfried Holding AG
    • 10.5.5.1. Company Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Recipharm AB
    • 10.5.6.1. Company Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. CordenPharma International
    • 10.5.7.1. Company Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Boehringer Ingelheim
    • 10.5.8.1. Company Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Piramal Pharma Solutions
    • 10.5.9.1. Company Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Aenova Group
    • 10.5.10.1. Company Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives
  • 10.5.11. Almac Group
    • 10.5.11.1. Company Overview
    • 10.5.11.2. Financial Performance
    • 10.5.11.3. Product Benchmarking
    • 10.5.11.4. Strategic Initiatives
  • 10.5.12. Jubilant Pharmova Limited
    • 10.5.12.1. Company Overview
    • 10.5.12.2. Financial Performance
    • 10.5.12.3. Product Benchmarking
    • 10.5.12.4. Strategic Initiatives
  • 10.5.13. Delpharm
    • 10.5.13.1. Company Overview
    • 10.5.13.2. Financial Performance
    • 10.5.13.3. Product Benchmarking
    • 10.5.13.4. Strategic Initiatives
  • 10.5.14. AbbVie Contract Manufacturing
    • 10.5.14.1. Company Overview
    • 10.5.14.2. Financial Performance
    • 10.5.14.3. Product Benchmarking
    • 10.5.14.4. Strategic Initiatives
  • 10.5.15. Next Pharma AB
    • 10.5.15.1. Company Overview
    • 10.5.15.2. Financial Performance
    • 10.5.15.3. Product Benchmarking
    • 10.5.15.4. Strategic Initiatives
  • 10.5.16. Rubicon Research Pvt. Ltd.
    • 10.5.16.1. Company Overview
    • 10.5.16.2. Financial Performance
    • 10.5.16.3. Product Benchmarking
    • 10.5.16.4. Strategic Initiatives
  • 10.5.17. Quotient Sciences
    • 10.5.17.1. Company Overview
    • 10.5.17.2. Financial Performance
    • 10.5.17.3. Product Benchmarking
    • 10.5.17.4. Strategic Initiatives
  • 10.5.18. SPI Pharma
    • 10.5.18.1. Company Overview
    • 10.5.18.2. Financial Performance
    • 10.5.18.3. Product Benchmarking
    • 10.5.18.4. Strategic Initiatives
  • 10.5.19. DPT Laboratories Ltd.
    • 10.5.19.1. Company Overview
    • 10.5.19.2. Financial Performance
    • 10.5.19.3. Product Benchmarking
    • 10.5.19.4. Strategic Initiatives
  • 10.5.20. Alcami Corporation
    • 10.5.20.1. Company Overview
    • 10.5.20.2. Financial Performance
    • 10.5.20.3. Product Benchmarking
    • 10.5.20.4. Strategic Initiatives